{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:54:59Z","timestamp":1789750499354,"version":"4.0.1"},"reference-count":32,"publisher":"Bioscientifica","issue":"2","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the predictive value of pretreatment thyroid autoantibody titers for thyroid immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, 181 patients with malignancies treated with ICIs between January 2022 and October 2025 were retrospectively analyzed. The patients were categorized based on the occurrence of thyroid irAEs. Risk factors and the impact of antibody titers were analyzed using logistic regression and Kaplan\u2013Meier methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thyroid irAEs occurred in 44 (24.3%) patients, predominantly including hypothyroidism (81.8%). Logistic regression revealed that baseline thyroid-stimulating hormone (TSH) levels, thyroid peroxidase antibody (TPOAb) positivity, and thyroglobulin antibody (TgAb) positivity were significant risk factors (P &amp;lt; 0.05). Kaplan\u2013Meier analysis revealed a significantly higher incidence of irAEs in patients with elevated baseline TPOAb and TgAb titers than in those with normal titers (P &amp;lt; 0.01). Notably, severely elevated TPOAb titers resulted in a significantly higher risk of irAEs than moderately elevated titers (P &amp;lt; 0.05), whereas the corresponding difference for TgAb titers was not significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Baseline TPOAb and TgAb titers are effective predictors of thyroid irAEs. Higher TPOAb titers are correlated with an increased risk, thereby supporting the utility of quantitative baseline screening for risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-26-0017","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:21:35Z","timestamp":1776435695000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":1,"title":["Predictive value of baseline thyroid autoantibody titers for ICI-associated thyroid adverse events in cancer"],"prefix":"10.1530","volume":"15","author":[{"given":"Li","family":"Jian","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Ou","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiyu","family":"Xia","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guhang","family":"Tang","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Yu","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1255-4660","authenticated-orcid":true,"given":"Qiquan","family":"Zhao","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Qinan Wu","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2026070714005892500_bib1","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.2174\/0929867329666220819115849","article-title":"Immune checkpoint inhibitors: recent clinical advances and future prospects","volume":"30","author":"Banday","year":"2023","journal-title":"Curr Med Chem"},{"key":"2026070714005892500_bib2","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer immunotherapy","volume":"184","author":"Dougan","year":"2021","journal-title":"Cell"},{"key":"2026070714005892500_bib3","doi-asserted-by":"crossref","first-page":"e008591","DOI":"10.1136\/jitc-2023-008591","article-title":"Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update","volume":"12","author":"Fletcher","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026070714005892500_bib4","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4049\/jimmunol.2200244","article-title":"Inhibition of IL-17A protects against thyroid immune-related adverse events while preserving checkpoint inhibitor antitumor efficacy","volume":"209","author":"Lechner","year":"2022","journal-title":"J Immunol"},{"key":"2026070714005892500_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2265.1995.tb01894.x","article-title":"The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey","volume":"43","author":"Vanderpump","year":"1995","journal-title":"Clin Endocrinol"},{"key":"2026070714005892500_bib6","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s40618-020-01480-6","article-title":"Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy","volume":"44","author":"Brilli","year":"2021","journal-title":"J Endocrinol Investig"},{"key":"2026070714005892500_bib7","doi-asserted-by":"crossref","first-page":"e009215","DOI":"10.1136\/jitc-2024-009215","article-title":"Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma","volume":"12","author":"Borgers","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026070714005892500_bib8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J Endocr Soc"},{"key":"2026070714005892500_bib9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12020-023-03323-9","article-title":"Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study","volume":"81","author":"Wu","year":"2023","journal-title":"Endocrine"},{"key":"2026070714005892500_bib10","doi-asserted-by":"crossref","first-page":"e3620","DOI":"10.1210\/clinem\/dgaa458","article-title":"Immune checkpoint inhibitor-induced thyroid dysfunction is associated with higher body mass index","volume":"105","author":"Pollack","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714005892500_bib11","doi-asserted-by":"crossref","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714005892500_bib12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1507\/endocrj.EJ22-0467","article-title":"Delayed-onset immune-related adverse events involving the thyroid gland by immune checkpoint inhibitors in combination with chemotherapy: a case report and retrospective cohort study","volume":"70","author":"Ueba","year":"2023","journal-title":"Endocr J"},{"key":"2026070714005892500_bib13","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-24-0328","article-title":"Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors","volume":"14","author":"Yamauchi","year":"2025","journal-title":"Eur Thyroid J"},{"key":"2026070714005892500_bib14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with Nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026070714005892500_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"2026070714005892500_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216954","article-title":"Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab","volume":"14","author":"Yamauchi","year":"2019","journal-title":"PLoS One"},{"key":"2026070714005892500_bib17","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026070714005892500_bib18","doi-asserted-by":"crossref","first-page":"e1056","DOI":"10.1210\/clinem\/dgad231","article-title":"Risk of thyroid dysfunction in PD-1 blockade is stratified by the pattern of TgAb and TPOAb positivity at baseline","volume":"108","author":"Zhou","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714005892500_bib19","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026070714005892500_bib20","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-021-01406-6","article-title":"Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade","volume":"27","author":"Andrews","year":"2021","journal-title":"Nat Med"},{"key":"2026070714005892500_bib21","doi-asserted-by":"crossref","first-page":"e2002","DOI":"10.1002\/onco.13918","article-title":"Real-world clinical and economic outcomes in selected immune-related adverse events among patients with cancer receiving immune checkpoint inhibitors","volume":"26","author":"Zheng","year":"2021","journal-title":"Oncologist"},{"key":"2026070714005892500_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb7495","article-title":"CD4+ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice","volume":"13","author":"Yasuda","year":"2021","journal-title":"Sci Transl Med"},{"key":"2026070714005892500_bib23","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1089\/thy.2017.0062","article-title":"Anti-PD-1 antibody therapy induces hashimoto's disease with an increase in peripheral blood follicular helper T cells","volume":"27","author":"Torimoto","year":"2017","journal-title":"Thyroid"},{"key":"2026070714005892500_bib24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"2026070714005892500_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg0675","article-title":"Clonally expanded, thyrotoxic effector CD8+ T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis","volume":"15","author":"Lechner","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026070714005892500_bib26","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41416-020-0736-7","article-title":"Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study","volume":"122","author":"Okada","year":"2020","journal-title":"Br J Cancer"},{"key":"2026070714005892500_bib27","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2410557","article-title":"Exploring risk factors for endocrine-related immune-related adverse events: insights from meta-analysis and Mendelian randomization","volume":"20","author":"Quan","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"2026070714005892500_bib28","doi-asserted-by":"crossref","first-page":"e4115","DOI":"10.1210\/clinem\/dgac467","article-title":"Elevated TSH level, TgAb, and prior use of ramucirumab or TKIs as risk factors for thyroid dysfunction in PD-L1 blockade","volume":"107","author":"Kobayashi","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714005892500_bib29","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/cas.14363","article-title":"Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors","volume":"111","author":"Kurimoto","year":"2020","journal-title":"Cancer Sci"},{"key":"2026070714005892500_bib30","doi-asserted-by":"crossref","first-page":"e1843","DOI":"10.1210\/clinem\/dgac059","article-title":"Association of antithyroid antibodies in checkpoint inhibitor-associated thyroid immune-related adverse events","volume":"107","author":"Muir","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714005892500_bib31","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3390\/molecules26040881","article-title":"Selenium biofortification: roles, mechanisms, responses and prospects","volume":"26","author":"Hossain","year":"2021","journal-title":"Molecules"},{"key":"2026070714005892500_bib32","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.3390\/nu14112234","article-title":"Selenium supplementation in pregnant women with autoimmune thyroiditis: a practical approach","volume":"14","author":"Minnetti","year":"2022","journal-title":"Nutrients"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/15\/2\/ETJ-26-0017.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/15\/2\/ETJ-26-0017.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-26-0017\/503416\/etj-26-0017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-26-0017\/503416\/etj-26-0017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:01:08Z","timestamp":1783447268000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/15\/2\/ETJ260017\/75641\/Predictive-value-of-baseline-thyroid-autoantibody"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-26-0017","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"ETJ260017"}}